We are live on ! Find out more
CERO

CERo Therapeutics
CERO

Delisted

CERO was delisted on the 30th of October, 2025.

Back to rankings

65 hedge funds and large institutions have $159M invested in CERo Therapeutics in 2022 Q3 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

260% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 5

167% more repeat investments, than reductions

Existing positions increased: 16 | Existing positions reduced: 6

25% more funds holding

Funds holding: 52 → 65 (+13)

7% more capital invested

Capital invested by funds: $149M → $159M (+$10.2M)

0% more ownership

Funds ownership: 0.04% → 0.04% (+0%)

Holders
65
Holders Change
+13
Holders Change %
+25%
% of All Funds
1.12%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
16
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Janus Henderson Group
Janus Henderson Group
United Kingdom
+$11.8M
2
HSBC Holdings
HSBC Holdings
United Kingdom
+$4.71M
3
MF
Magnetar Financial
Illinois
+$3.2M
4
Marshall Wace
Marshall Wace
United Kingdom
+$2.14M
5
MC
Meteora Capital
Florida
+$1.65M

Top Sellers

Rank Fund Capital Flow
1
CF
Cantor Fitzgerald
New York
-$7.51M
2
HIM
HGC Investment Management
Ontario, Canada
-$5.04M
3
LA
Linden Advisors
New York
-$4.71M
4
WP
Woodline Partners
California
-$3.01M
5
CL
CSS LLC
Illinois
-$2.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
SC
51
Sculptor Capital
New York
$296K – – –
Verition Fund Management
52
Verition Fund Management
Connecticut
$264K +$262K +13 New
DCM
53
Dupont Capital Management
Delaware
$253K – – –
Calamos Advisors
54
Calamos Advisors
Illinois
$253K +$262K +13 New
SV
55
Starboard Value
New York
$215K – – –
HF
56
HRT Financial
New York
$138K – – –
Geode Capital Management
57
Geode Capital Management
Massachusetts
$106K +$101K +5 New
OMC
58
Old Mission Capital
Illinois
$106K +$101K +5 New
GCL
59
Glazer Capital LLC
New York
$103K +$101K +5 New
DAM
60
Deltec Asset Management
New York
$101K – – –
SCM
61
Segantii Capital Management
Hong Kong
$101K – – –
RCM
62
Robinson Capital Management
Michigan
$76K +$20.1K +1 +33%
EC
63
Elequin Capital
New York
$16K +$20.1K +1 New
UBS Group
64
UBS Group
Switzerland
$15K +$20.1K +1 New
Bank of Montreal
65
Bank of Montreal
Ontario, Canada
$322 +$322K +16 New
CF
66
Cantor Fitzgerald
New York
– -$7.51M -375 Closed
WP
67
Woodline Partners
California
– -$3.01M -150 Closed
CL
68
CSS LLC
Illinois
– -$2.77M -138 Closed
PMAM
69
Picton Mahoney Asset Management
Ontario, Canada
– -$1.5M -75 Closed
CM
70
Crestline Management
Texas
– -$251K -13 Closed
1 2
3

CERO Hedge Fund Activity: Q3 2022 in Review

65 of the 5,806 institutional investors tracked by Wall St. Rank reported a position in CERo Therapeutics (CERO) for Q3 2022, worth a combined $159M — up 6.8% from $149M a quarter earlier.

Buyers outnumbered sellers: 18 funds opened new CERO positions and 5 closed out — a net gain of 13 holders — while 16 added to existing stakes and 6 trimmed.

The largest buyer was Janus Henderson Group, adding an estimated $11.8M. The largest seller was Cantor Fitzgerald, exiting entirely with an estimated $7.51M sold.

  • 65 institutional investors held CERo Therapeutics (CERO) as of Q3 2022, up from 52 in Q2 2022.
  • Funds reported $159M of CERo Therapeutics stock for Q3 2022, up 6.8% quarter-over-quarter.
  • 18 funds opened new CERo Therapeutics positions in Q3 2022 and 5 closed out, a net change of +13 holders.
  • The largest CERo Therapeutics buyer in Q3 2022 was Janus Henderson Group, an estimated $11.8M added.
  • The largest CERo Therapeutics seller in Q3 2022 was Cantor Fitzgerald, an estimated $7.51M sold.

Based on aggregated 13F filings for Q3 2022.